The soybean isoflavones, genistein (GEN) Phenoxodiol (2H-1-benzopyran-7-0, 3-(hydroxylphenyl) 
Recently, a molecular target protein of PXD was identified, the tumour-specific surface molecule tNOX, inhibition of which, following PXD ligation [12] , compromises plasma membrane electron transport (PMET) and drives actively proliferating cells to apoptosis [13] . Moreover, PXD possesses antiangiogenic properties [14] and protects cells from cisplatin-induced neurite toxicity in vitro [15] . In vivo animal tumour models have demonstrated the ability of PXD to act either as a chemopreventive agent in DMBA-induced mammary tumour-bearing rats [4] or as a chemosensitizer along with various chemotherapeutic agents (e.g. carboplatin, gemcitabine, topotecan) against xenografted epithelial ovarian tumours [5, 16] .
Based on the aforementioned in vitro and in vivo reports, the drug was granted a fast track approval by FDA in 2004 [17] or grade III lymphocytopenia, the latter not showing any correlation with increasing dose levels of PXD [18] . In both studies, no objective responses were recorded; however, some patients experienced stabilization of their disease up to 6 
months after treatment. PXD has now entered phase II/III clinical trials, administered in principle in patients with hormone related cancers, such as ovarian, prostate and cervical. Although PXD in principle is considered to preferentially target cancer cells, a most elegant recent report by Herst et al. [13], provided a possible explanation of the development of lymphocytopenia in PXD-treated patients; the drug through PMET and sphingosine kinase inhibition, induces apoptosis of rapidly growing cells, such as cancer cells and activated T cells.
In order to directly assess the effect of PXD monotherapy on immune cells, we used in vitro and in vivo assays initially aiming to precisely determine the dose toxicity of PXD to lymphocytes. We report that PXD at low concentrations (0.05-0.5 g/ml), enhances in vitro peripheral blood mononuclear cell (PBMC) 
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Statistical analysis
The data were analysed by the Student's t-test and statistical significance was presumed at significance level of 5% (P Ͻ 0.05).
Results
PXD inhibits PBMC proliferation and reduces PBMC viability
Previous reports [5, 11, 13] [19] . PXD significantly enhanced normal donor PBMC cytotoxicity for K562 cells at 0.1-0.2 g/ml ( Fig. 2A) and that of cancer patients at 0.05-0.5 g/ml (Fig. 2B) . In both cases, maximal effect (1.5-and 1.8-fold increase, for healthy donors and cancer patients, respectively) was recorded at [4, 11, 12] , PXD was shown to selectively target cancer cells [3, [10] [11] [12] 20] . However, high PXD concentrations stimulated apoptosis in normal trophoblasts [9] , exerted antiproliferative effects on normal endothelial cells [14] and induced toxicity in neurites [15] . Moreover, activated murine T cells exposed to 10 M PXD died within 48 hrs [13] . The latter data are in accordance with our results, where PXD at concentrations Ͼ1 g/ml greatly reduced both PBMC proliferation and cell viability (Fig. 1) [21] . In addition, GEN fed by oral gavage increased interferon-␥ production, CTL activation and NK cytotoxicity in mice [22, 23] . These results prompted us to investigate whether PXD could affect specific lymphocyte functions. Indeed, PXD significantly enhanced (by 1.5-fold) healthy donor-derived PBMC cytotoxicity against NK-sensitive targets (K562) and this effect was more pronounced with cancer patient-derived PBMC (Fig. 2) [4] and PXD combined with chemotherapeutics arrested chemoresistant ovarian cancer expansion [5, 16] . However, and in agreement with our results, lower PXD doses given as monotherapy were also effective [5] .
H-Thymidine incorporation (A) and cell viability (B) induced by phenoxodiol (PXD), genistein (GEN) and daidzein (DZ
cells was not increased at any PXD, GEN or DZ concentration tested and remained at the levels of non-stimulated control T cells (Յ7%; data not shown).
PXD reduces tumour mass and prolongs survival of cancer-bearing mice in vivo
Fig. 4 Tumour volume (A) and overall survival (B) of CT-26 tumour-bearing mice treated with flavonoids. Mice received five i.p. doses of the compounds genistein (GEN), daidzein (DZ) or phenoxodiol (PXD20) at 20 mg/kg or PXD at 10 mg/kg (PXD10). Control mice received PBS. Tumour growth and survival were monitored every 2-3 days over a total of 38 days after cancer cell inoculation and tumour volume was calculated as described in 'Materials
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